USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mackay Memorial Hospital

USPTO PatentsView assignee record - 40 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

12.3

Avg claims per patent

-42%

5-year grant velocity

The verdict

According to USPTO PatentsView, Mackay ranks #8,069 of 50,000 tracked US assignees by granted-patent volume, with 40 patents across 23 technology areas.

#8,069
of 50,000 US assignees by volume: Top 40%
by Innovation Score (38.7/100): 12.3
avg claims per patent: -42%
grant velocity, last 5 yrs

Portfolio overview

Mackay Memorial Hospital has been granted 40 US utility patents between 2015 and 2025, placing Mackay Memorial Hospital at #8,069 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Mackay Memorial Hospital is one of the more focused assignees in the PatentsView dataset. By volume, Mackay sits between Michigan Technological University (40 patents, rank #8,070) and Milacron Llc (40 patents, rank #8,078) - the closest US assignees by grant volume. The composite Innovation Score of 38.7/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 14 grants, compared with 24 in the 2015–2019 window, a -42% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Mackay Memorial Hospital's 12.3 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 23 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Michigan Technolo…

40
Mitsubishi Electr…

40
MKW Alloy

40
MRI Interventions

40
Machine Zone

40
Marelli

40
Markem-imaje

40
Milacron

40
Mackay Memorial H… ◀

40

What this shows Mackay holds 40 patents at rank #8,074, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mackay

By rank, the assignees closest to #8,074 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Mackay's primary technology class.

Mackay's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mackay Memorial Hospital patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	7.5%
2016	6	15.0%
2017	6	15.0%
2018	2	5.0%
2019	7	17.5%
2020	6	15.0%
2021	4	10.0%
2022	1	2.5%
2023	2	5.0%
2024	1	2.5%
2025partial year	2	5.0%

Which technologies does Mackay Memorial Hospital patent most?

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 19

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 18

C07K - PEPTIDES 12

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 8

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 5

G06T - IMAGE DATA PROCESSING OR GENERATION, IN GENERAL 5

G06F - ELECTRIC DIGITAL DATA PROCESSING 5

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 3

C07D - HETEROCYCLIC COMPOUNDS 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 2

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 2

G06V - IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING 2

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

Top 15 of 23 technology areas

Grant record at a glance

Portfolio Volume 40 grants

CPC subclasses 23

Avg. claims / grant 12.3

Velocity -42%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#8,069

of 50,000 tracked assignees

Innovation Score

38.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Mackay Memorial Hospital rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mackay Memorial Hospital ranks #8,069 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mackay Memorial Hospital hold?

Mackay Memorial Hospital holds 40 US utility patents granted between 2015 and 2025, spanning 23 technology areas.

What is Mackay Memorial Hospital's Innovation Score?

Mackay Memorial Hospital has an Innovation Score of 38.7 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mackay Memorial Hospital focus on?

Mackay Memorial Hospital's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 19 patents. Grants appear in 23 CPC subclasses total.

Is Mackay Memorial Hospital's patent grant rate increasing or decreasing?

Mackay Memorial Hospital's recent grant velocity is -42% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Mackay Memorial Hospital's patents?

Mackay Memorial Hospital's patents average 12.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mackay Memorial Hospital patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Mackay's 40 grants land it in the top 40% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Mackay ranks #8,069 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.